Standard Biotools (LAB) Acquisitions (2014 - 2024)

Standard Biotools' (LAB) quarterly Acquisitions came in at -$278.6 million in Q4 2024, down 199.51% on a QoQ basis from $280.0 million in Q1 2024.

Standard Biotools (LAB) Acquisitions (2014 - 2024) Analysis & Trends

Standard Biotools (LAB) has 3 years of Acquisitions data on file, last reported at -$278.6 million in Q4 2024.

On a quarterly basis, Acquisitions changed N/A year-over-year to -$278.6 million in Q4 2024; TTM through Sep 2025 was -$278.6 million, a 199.51% decrease from a year earlier, with the FY2024 full-year figure at $1.4 million, changed N/A from the prior year.
Acquisitions for Q4 2024 stood at -$278.6 million, down from $280.0 million in the prior quarter.
Over the last five years, Acquisitions for LAB reached as high as $280.0 million in Q1 2024 and fell as low as -$278.6 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Abbott Laboratories	183.64 Bn	176.34 Bn	6.27 Bn	-
2	Stryker	129.04 Bn	126.16 Bn	3.81 Bn	22.00 Mn
3	Medtronic	109.04 Bn	99.82 Bn	6.41 Bn	406.00 Mn
4	Boston Scientific	68.54 Bn	67.08 Bn	3.61 Bn	523.00 Mn
5	Edwards Lifesciences	48.67 Bn	45.00 Bn	1.29 Bn	-
6	Dexcom	28.40 Bn	27.28 Bn	750.30 Mn	-
7	GE HealthCare Technologies	28.37 Bn	26.08 Bn	1.98 Bn	2.30 Bn
8	Smith & Nephew	26.92 Bn	26.34 Bn	-	-
9	Koninklijke Philips	25.48 Bn	22.36 Bn	2.07 Bn	-268.10 Mn
10	Standard Biotools	309.09 Mn	-146.09 Mn	11.31 Mn	-

Download Data